^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
Title:

Poor Prognosis of Pulmonary Adenosquamous Carcinoma with NRAS and HRAS Double Mutation

Published date:
02/17/2021
Excerpt:
...58-year-old male smoker who was diagnosed with stage IV lung adenosquamous carcinoma. A rare NRAS and HRAS double mutation was detected in the primary tumor and lymph node samples using next-generation sequencing (NGS). The patient showed rapid disease progression and passed away due to respiratory failure after 15 days of osimertinib in combination with cisplatin....HRAS Q61L and NRAS Q61K were consistently found in the primary tumor and lymph nodes...
Secondary therapy:
cisplatin
DOI:
10.2147/OTT.S295813